✦ LIBER ✦

Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs)

✍ Scribed by Sun Jin Sym; Min-Hee Ryu; Jae-Lyun Lee; Heung Moon Chang; Tae-Won Kim; Hee Cheol Kim; Ki Hun Kim; Jeong Hwan Yook; Byung Sik Kim; Yoon-Koo Kang

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 105 KB
Volume: 98
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.21065

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Surgical treatment of patients with init

Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate

✍ Piotr Rutkowski; Zbigniew Nowecki; Pawel Nyckowski; Wirginiusz Dziewirski; Urszu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB

Adjuvant and down-staging treatment with

Adjuvant and down-staging treatment with imatinib in gastrointestinal stromal tumors

✍ B. Nilsson; A. Andersson; H. Ahlman 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 51 KB

The role of high-dose imatinib in the ma

The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor

✍ Alessandro Gronchi; Jean-Yves Blay; Jonathan C. Trent 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB

Correlation of immunophenotype with prog

Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate

✍ Lucian R. Chirieac; Jonathan C. Trent; Dejka M. Steinert; Haesun Choi; Ying Yang 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 414 KB

Adjuvant Imatinib treatment after R0 res

Adjuvant Imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: A median follow-up of 44 months

✍ Wei-Zhong Jiang; Guo-Xian Guan; Hui-Shan Lu; Ying-Hong Yang; De-Yong Kang; He-Gu 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

Expression of Bcl-2 in gastrointestinal

Expression of Bcl-2 in gastrointestinal stromal tumors : Correlation with progression-free survival in 81 patients treated with imatinib mesylate

✍ Dejka M. Steinert; Mauricio Oyarzo; Xuemei Wang; Haesun Choi; Peter F. Thall; L. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 1 views

## Abstract ## BACKGROUND The natural history of gastrointestinal stromal tumor (GIST) has been revolutionized by imatinib mesylate (imatinib) therapy. Before imatinib, Bcl‐2 expression in GIST was associated with a worse prognosis or added no additional prognostic value. To the authors' knowledge